Aspirin low-dose (cancer chemoprevention context)
Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.
| ID | DRUG-ASPIRIN-LOW-DOSE-CHEMOPREVENTION |
|---|---|
| Tipo | Fármaco |
| Aliaces | Ácido acetilsalicílico 81 mgDosis baja de aspirina (quimioprevención del cáncer)Aspirina para bebésBayer Aspirina (81 mg)CardiomagnilAAS de dosis bajaАцетилсаліцилова кислота низькодозова (хіміопрофілактика раку) |
| Situación | reviewed 2026-05-18 | pending_clinical_signoff |
| Enfermedades | Ninguna declarada |
| Fuentes | SRC-NCCN-COLON-2025 SRC-USPSTF-CRC-2021 |
Datos sobre drogas
| Clase | Non-selective cyclooxygenase (COX-1/COX-2) inhibitor; antiplatelet at low dose |
|---|---|
| Mecanismo | Irreversibly acetylates serine-530 of platelet COX-1, blocking thromboxane A2 synthesis for the platelet's lifespan (~7-10 days). Cancer-prevention rationale: COX-2 suppression in colonic mucosa reduces prostaglandin-driven adenoma growth; long-term low-dose aspirin reduces CRC incidence and mortality in Lynch syndrome (CAPP2 RCT, 10-year follow-up: ~50% reduction in colorectal cancers with 600 mg/day, durable benefit; subsequent dosing studies favor 100 mg/day for risk/benefit). |
| Dosificación típica | Cancer chemoprevention (Lynch syndrome / hereditary CRC risk reduction): 81-100 mg PO daily ongoing (CAPP2 used 600 mg/day; CaPP3 ongoing dose-comparison trial supports 100 mg as effective with lower bleeding risk). Duration: ≥2 years to begin, ≥5-10 years for full benefit. Take with food. Note USPSTF 2022 withdrew prior CRC- prevention recommendation for general population (net benefit uncertain); Lynch-specific recommendation retained by InSiGHT/NCCN. |
| Ucrania registrada | Cierto |
| NSZU reembolsado | Falso |
| Ucrania verificada por última vez | 2026-05-18 |
Notas
STUB — v0.2 chemoprevention-workstream authoring; pending two-Clinical- Co-Lead signoff per CHARTER §6.1 dev-mode. CHEMOPREVENTION CONTEXT — separate entity from DRUG-ASPIRIN (which carries oncology supportive- care indications, e.g., VTE prophylaxis in lenalidomide MM). Use here reflects long-term low-dose ASA for colorectal cancer (and possibly other GI/breast/prostate) risk reduction. Strongest evidence in Lynch syndrome (CAPP2, NCT00188266; 10-year follow-up in Lancet 2020). USPSTF 2022 reversed prior 2016 grade B and now reports insufficient evidence (I statement) for routine general-population CRC chemoprevention due to bleeding-risk re-weighting (ASPREE trial). Engine should not auto-recommend without (a) confirmed Lynch / hereditary CRC risk, (b) bleeding-risk assessment, (c) shared decision-making documented. Dual cardiovascular benefit may justify use in higher-CV-risk patients with hereditary CRC.
Utilizado por
No se encuentran referencias inversas en el corpus YAML.